| 價(jià)格 | 詢價(jià) |
| 包裝 | 1removed |
| 最小起訂量 | 1removed |
| 發(fā)貨地 | 上海 |
| 更新日期 | 2026-05-08 |
| 中文名稱:化合物 (R)-ND-336 | 英文名稱:(R)-ND-336 |
| CAS:2252493-33-5 | 品牌: TargetMol |
| 產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 產(chǎn)品類別: 抑制劑 | |
| 貨號(hào): T001|T61491 |
| 名稱 | (R)-ND-336 |
| 描述 | (R)-ND-336 is a highly potent and selective MMP-9 inhibitor, displaying a K i value of 19 nM. It also exhibits inhibitory activity against MMP-2 (K i = 127 nM) and MMP-14 (K i =119 nM). With its significant potential, (R)-ND-336 is being investigated in the field of diabetic foot ulcers (DFUs) research [1]. |
| 體外活性 | (R)-ND-336 poorly inhibits other MMPs (K i >100 μM). (R)-ND-336 has a long residence time (the time the inhibitor is bound to MMP-9, calculated as 1/k off ) of 300 min [1]. A favorable IC50value of 143 μM afforded a therapeutic index (IC 50 /K i for MMP-9) ratio of 7530, indicating that (R)-ND-336 is not cytotoxic [1]. |
| 體內(nèi)活性 | (R)-ND-336 (50 μg/wound/day for 14 days) accelerates wound healing faster [1]. (R)-ND-336 has an AUC of 1.3 μM min after topical administration and 35 μM min following intravenous dosing, for an AUC top /AUC iv ratio of 3.7%, indicating minimal absorption after topical administration in db/db mice [1]. Animal Model: Female db/db mice (BKS.Cg-Dock7 m+/+ Lepr db /J, 8-weeks old, ~40 g body weight) [1] Dosage: 50 μg Administration: Wound; once a day for 14 days Result: Accelerated wound healing faster and showed complete inhibition of MMP-9. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 相關(guān)產(chǎn)品 | Doxycycline (hyclate) | Rhamnose monohydrate | Astragaloside IV | Anethole | Meloxicam | Doxycycline | Glucosamine | Methylchloroisothiazolinone/Methylisothiazolinone Mixture | Chondroitin sulfate | 3-Aminopropionitrile fumarate (2:1) | Propoxur | Edaravone |
| 成立日期 | 2013-04-18 (14年) | 注冊資本 | 589.8595萬人民幣 |
| 員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
| 主營行業(yè) | 中間體,天然產(chǎn)物,生物化工,化學(xué)試劑,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
|---|---|---|---|---|
| 詢價(jià) |
VIP5年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2026-07-21 | |
| 詢價(jià) |
VIP1年
|
陜西締都醫(yī)藥有限責(zé)任公司
|
2026-04-22 | |
| 詢價(jià) |
VIP7年
|
武漢克米克生物醫(yī)藥技術(shù)有限公司
|
2026-07-30 |